CN104302649B - 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法 - Google Patents
基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法 Download PDFInfo
- Publication number
- CN104302649B CN104302649B CN201380012483.0A CN201380012483A CN104302649B CN 104302649 B CN104302649 B CN 104302649B CN 201380012483 A CN201380012483 A CN 201380012483A CN 104302649 B CN104302649 B CN 104302649B
- Authority
- CN
- China
- Prior art keywords
- pyrimidin
- mmol
- pyrazolo
- compound
- piperazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *N(*)C(C=C[n]1nccc1N)=C Chemical compound *N(*)C(C=C[n]1nccc1N)=C 0.000 description 5
- AFVKKRXDGYHAQP-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c(cc[n]1nc2)nc1c2-c(cccn1)c1OC)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c(cc[n]1nc2)nc1c2-c(cccn1)c1OC)=O AFVKKRXDGYHAQP-UHFFFAOYSA-N 0.000 description 2
- MFINLMYILJJJND-UHFFFAOYSA-N Brc(cn[n]1cc2)c1nc2N1CCNCC1 Chemical compound Brc(cn[n]1cc2)c1nc2N1CCNCC1 MFINLMYILJJJND-UHFFFAOYSA-N 0.000 description 1
- NZVGDAUQGIPJKS-INIZCTEOSA-N CC(C)(C)OC(N1[C@H](CNc(cc[n]2nc3)nc2c3-c(cccc2)c2OC)CCC1)=O Chemical compound CC(C)(C)OC(N1[C@H](CNc(cc[n]2nc3)nc2c3-c(cccc2)c2OC)CCC1)=O NZVGDAUQGIPJKS-INIZCTEOSA-N 0.000 description 1
- DIMLBYMJHJEEOJ-NSHDSACASA-N CC(C)(C)OC(N1[C@H](CNc2nc3c(C(F)(F)F)cn[n]3cc2)CCC1)=O Chemical compound CC(C)(C)OC(N1[C@H](CNc2nc3c(C(F)(F)F)cn[n]3cc2)CCC1)=O DIMLBYMJHJEEOJ-NSHDSACASA-N 0.000 description 1
- GIOFAIKYNCSSTB-LBPRGKRZSA-N CC(C)(C)OC(N1[C@H](CNc2nc3ccn[n]3cc2)CCC1)=O Chemical compound CC(C)(C)OC(N1[C@H](CNc2nc3ccn[n]3cc2)CCC1)=O GIOFAIKYNCSSTB-LBPRGKRZSA-N 0.000 description 1
- QDNRGSZLDNADBY-NSHDSACASA-N CC(C)(C)OC(N[C@@H](CC1)CN1c(cc[n]1nc2)nc1c2[Br]=C)=O Chemical compound CC(C)(C)OC(N[C@@H](CC1)CN1c(cc[n]1nc2)nc1c2[Br]=C)=O QDNRGSZLDNADBY-NSHDSACASA-N 0.000 description 1
- MQHVRERVQJNPBQ-GOSISDBHSA-N CC(C)(C)[C@@H](C(N(CC1)CCN1c(cc[n]1nc2)nc1c2-c1cccnc1OC)=O)N Chemical compound CC(C)(C)[C@@H](C(N(CC1)CCN1c(cc[n]1nc2)nc1c2-c1cccnc1OC)=O)N MQHVRERVQJNPBQ-GOSISDBHSA-N 0.000 description 1
- HRIFHNOAWYENEC-KRWDZBQOSA-N CC(C)C[C@H](C)C(N(CC1)CCN1c(cc[n]1nc2)nc1c2-c1cccnc1OC)=O Chemical compound CC(C)C[C@H](C)C(N(CC1)CCN1c(cc[n]1nc2)nc1c2-c1cccnc1OC)=O HRIFHNOAWYENEC-KRWDZBQOSA-N 0.000 description 1
- DYEMAGIQCRKEGO-UHFFFAOYSA-N CC(C)OC(N(C)CCNc(cc[n]1nc2)nc1c2-c(ccnc1)c1OC)=O Chemical compound CC(C)OC(N(C)CCNc(cc[n]1nc2)nc1c2-c(ccnc1)c1OC)=O DYEMAGIQCRKEGO-UHFFFAOYSA-N 0.000 description 1
- BLIQHWVRJJIHLP-UHFFFAOYSA-N CC(C)OC(N(CC1)CCN1c(cc[n]1nc2)nc1c2-c(cccc1)c1OC)=O Chemical compound CC(C)OC(N(CC1)CCN1c(cc[n]1nc2)nc1c2-c(cccc1)c1OC)=O BLIQHWVRJJIHLP-UHFFFAOYSA-N 0.000 description 1
- JUSUMSXFHDTEMR-UHFFFAOYSA-N CC(C)OC(N(CC1)CCN1c(cc[n]1nc2)nc1c2Br)=O Chemical compound CC(C)OC(N(CC1)CCN1c(cc[n]1nc2)nc1c2Br)=O JUSUMSXFHDTEMR-UHFFFAOYSA-N 0.000 description 1
- VFCUOYBRMOCPFC-UHFFFAOYSA-N CC(C)OC(N(CC1)CCN1c(cc[n]1nc2)nc1c2C1=CC=CN(C)C1=C)=O Chemical compound CC(C)OC(N(CC1)CCN1c(cc[n]1nc2)nc1c2C1=CC=CN(C)C1=C)=O VFCUOYBRMOCPFC-UHFFFAOYSA-N 0.000 description 1
- KPLRELRHNCQSFD-UHFFFAOYSA-N COCC(C(N(CC1)CCN1c(cc[n]1nc2)nc1c2-c1cccnc1OC)=O)=N Chemical compound COCC(C(N(CC1)CCN1c(cc[n]1nc2)nc1c2-c1cccnc1OC)=O)=N KPLRELRHNCQSFD-UHFFFAOYSA-N 0.000 description 1
- IYNBELLOHXMHJN-UHFFFAOYSA-N COCCOC(N(CC1)CCN1c(cc[n]1nc2)nc1c2-c(cccn1)c1OC)=O Chemical compound COCCOC(N(CC1)CCN1c(cc[n]1nc2)nc1c2-c(cccn1)c1OC)=O IYNBELLOHXMHJN-UHFFFAOYSA-N 0.000 description 1
- IYSBSUPWYUVHKG-UHFFFAOYSA-N Clc(cc[n]1nc2)nc1c2Br Chemical compound Clc(cc[n]1nc2)nc1c2Br IYSBSUPWYUVHKG-UHFFFAOYSA-N 0.000 description 1
- WEPRLWNMBTYGGD-UHFFFAOYSA-N Clc1nc2ccn[n]2cc1 Chemical compound Clc1nc2ccn[n]2cc1 WEPRLWNMBTYGGD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608765P | 2012-03-09 | 2012-03-09 | |
| US61/608,765 | 2012-03-09 | ||
| PCT/US2013/029056 WO2013134228A1 (en) | 2012-03-09 | 2013-03-05 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104302649A CN104302649A (zh) | 2015-01-21 |
| CN104302649B true CN104302649B (zh) | 2017-06-23 |
Family
ID=47892052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380012483.0A Active CN104302649B (zh) | 2012-03-09 | 2013-03-05 | 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US8946415B2 (enExample) |
| EP (1) | EP2834243B1 (enExample) |
| JP (1) | JP6418950B2 (enExample) |
| KR (1) | KR101965025B1 (enExample) |
| CN (1) | CN104302649B (enExample) |
| AR (1) | AR090292A1 (enExample) |
| AU (1) | AU2013230128B2 (enExample) |
| BR (1) | BR112014022000A8 (enExample) |
| CA (1) | CA2866143C (enExample) |
| DK (1) | DK2834243T3 (enExample) |
| ES (1) | ES2676224T3 (enExample) |
| HU (1) | HUE038786T2 (enExample) |
| IL (1) | IL234486A (enExample) |
| IN (1) | IN2014DN07384A (enExample) |
| MX (2) | MX381849B (enExample) |
| NZ (1) | NZ630721A (enExample) |
| PL (1) | PL2834243T3 (enExample) |
| PT (1) | PT2834243T (enExample) |
| RU (1) | RU2014140735A (enExample) |
| SG (1) | SG11201405561RA (enExample) |
| TR (1) | TR201808280T4 (enExample) |
| TW (1) | TW201341386A (enExample) |
| UY (1) | UY34668A (enExample) |
| WO (1) | WO2013134228A1 (enExample) |
| ZA (1) | ZA201406149B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX381849B (es) | 2012-03-09 | 2025-03-13 | Lexicon Pharmaceuticals Inc | Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso. |
| EP2822559B1 (en) | 2012-03-09 | 2018-05-02 | Lexicon Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and uses thereof |
| US8901305B2 (en) | 2012-07-31 | 2014-12-02 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
| US9708337B2 (en) | 2013-02-22 | 2017-07-18 | Bristol-Myers Squibb Company | Aryl amide-based kinase inhibitors |
| TW201542550A (zh) * | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
| EP3054955B1 (en) | 2013-10-11 | 2018-05-30 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| WO2015112806A2 (en) | 2014-01-24 | 2015-07-30 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| EA201691397A1 (ru) * | 2014-01-31 | 2016-11-30 | Бристол-Майерс Сквибб Компани | Хинолиновые ингибиторы киназы |
| TW201620911A (zh) * | 2014-03-17 | 2016-06-16 | 雷西肯製藥股份有限公司 | 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法 |
| US20170239249A1 (en) * | 2014-09-30 | 2017-08-24 | Bristol-Myers Squibb Company | Quinazoline-based kinase inhibitors |
| PL3233863T3 (pl) * | 2014-12-15 | 2024-11-12 | Cmg Pharmaceutical Co., Ltd. | Związki heteroarylowe ze skondensowanymi pierścieniami i ich zastosowanie jako inhibitorów trk |
| US10174044B2 (en) | 2015-04-10 | 2019-01-08 | Bristol-Myers Squibb Company | Fused pyridines as kinase inhibitors |
| ES2864839T3 (es) | 2015-07-02 | 2021-10-14 | Turning Point Therapeutics Inc | Macrociclos de diarilo quirales como moduladores de proteína quinasas |
| ES2979111T3 (es) | 2015-07-06 | 2024-09-24 | Turning Point Therapeutics Inc | Polimorfo de macrociclo de diarilo |
| MX383823B (es) | 2015-07-21 | 2025-03-14 | Turning Point Therapeutics Inc | Macrociclos de diarilo quirales y usos de los mismo. |
| HK1256751A1 (zh) | 2015-11-02 | 2019-10-04 | Janssen Pharmaceutica Nv | [1，2，4]三唑并[1，5-a]嘧啶-7-基化合物 |
| CN109715165A (zh) | 2016-07-28 | 2019-05-03 | Tp生物医药公司 | 巨环激酶抑制剂 |
| ES2912264T3 (es) | 2016-11-02 | 2022-05-25 | Janssen Pharmaceutica Nv | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2 |
| EA039102B1 (ru) | 2016-11-02 | 2021-12-03 | Янссен Фармацевтика Нв | Соединения [1,2,4]триазоло[1,5-a]пиримидина в качестве ингибиторов pde2 |
| TWI764950B (zh) * | 2016-11-02 | 2022-05-21 | 比利時商健生藥品公司 | Ｐｄｅ２抑制劑 |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| US11046698B2 (en) | 2017-07-28 | 2021-06-29 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| MY201925A (en) | 2017-07-28 | 2024-03-23 | Turning Point Therapeutics Inc | Macrocyclic compounds and uses thereof |
| AU2018383571B2 (en) * | 2017-12-15 | 2023-09-21 | Pyramid Biosciences, Inc. | 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1H-pyrazol-1-yl)pyrazolo(1,5-a)pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer |
| JP7194188B2 (ja) | 2017-12-19 | 2022-12-21 | ターニング・ポイント・セラピューティクス・インコーポレイテッド | 疾患を治療するための大環状化合物 |
| WO2019120194A1 (zh) * | 2017-12-22 | 2019-06-27 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的吡唑并[1,5-a]嘧啶化合物及其药物组合物及用途 |
| CN109575025B (zh) | 2018-01-23 | 2020-09-11 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑并[1,5-a]嘧啶类的大环化合物 |
| WO2020063751A1 (en) * | 2018-09-27 | 2020-04-02 | Fochon Pharmaceuticals, Ltd. | Substituted imidazo [1, 2-a] pyridine and [1, 2, 4] triazolo [1, 5-a] pyridine compounds as ret kinase inhibitors |
| US11414431B2 (en) * | 2018-10-15 | 2022-08-16 | Nimbus Lakshmi, Inc. | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors |
| EP4138844A1 (en) | 2020-04-21 | 2023-03-01 | Lexicon Pharmaceuticals, Inc. | 4-(3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)piperazine for use in the the treatment of cov-229e or cov-oc43 coronaviruses infections |
| EP4138829A1 (en) | 2020-04-21 | 2023-03-01 | Lexicon Pharmaceuticals, Inc. | Aak1 inhibitors for use in treating viral infections |
| US11478733B2 (en) | 2020-11-24 | 2022-10-25 | Caterpillar Inc. | Filter interlock with tabs mating with a pedestal or a housing |
| TW202525819A (zh) * | 2023-09-08 | 2025-07-01 | 加拿大商薩泰洛斯生物科學公司 | Ａｐ２相關激酶１抑制劑及其用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1236780A (zh) * | 1998-03-11 | 1999-12-01 | 弗·哈夫曼-拉罗切有限公司 | 吡唑并嘧啶和吡唑并三嗪 |
| WO2011087999A1 (en) * | 2010-01-14 | 2011-07-21 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidines as mark inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| JP4847275B2 (ja) * | 2005-10-21 | 2011-12-28 | 田辺三菱製薬株式会社 | ピラゾロ［１，５−ａ］ピリミジン化合物 |
| KR20090073121A (ko) | 2006-09-29 | 2009-07-02 | 노파르티스 아게 | Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘 |
| US20120058997A1 (en) * | 2006-11-06 | 2012-03-08 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| BRPI0912668A2 (pt) * | 2008-05-13 | 2016-01-26 | Irm Llc | composto e composições como inibidores de quinase |
| KR101853026B1 (ko) * | 2008-10-22 | 2018-04-27 | 어레이 바이오파마 인크. | ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５ａ］ 피리미딘 화합물 |
| AR077468A1 (es) * | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| TW201113286A (en) | 2009-09-03 | 2011-04-16 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors |
| EP3409278B8 (en) * | 2011-07-21 | 2020-11-04 | Sumitomo Dainippon Pharma Oncology, Inc. | Heterocyclic protein kinase inhibitors |
| MX381849B (es) | 2012-03-09 | 2025-03-13 | Lexicon Pharmaceuticals Inc | Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso. |
| HK1199814A1 (en) * | 2012-03-09 | 2015-07-24 | Lexicon Pharmaceuticals, Inc. | Inhibition of adaptor associated kinase 1 for the treatment of pain |
| EP2822559B1 (en) | 2012-03-09 | 2018-05-02 | Lexicon Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and uses thereof |
| TW201620911A (zh) * | 2014-03-17 | 2016-06-16 | 雷西肯製藥股份有限公司 | 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法 |
-
2013
- 2013-03-05 MX MX2017002117A patent/MX381849B/es unknown
- 2013-03-05 US US13/785,355 patent/US8946415B2/en active Active
- 2013-03-05 HU HUE13710250A patent/HUE038786T2/hu unknown
- 2013-03-05 BR BR112014022000A patent/BR112014022000A8/pt not_active Application Discontinuation
- 2013-03-05 SG SG11201405561RA patent/SG11201405561RA/en unknown
- 2013-03-05 RU RU2014140735A patent/RU2014140735A/ru not_active Application Discontinuation
- 2013-03-05 MX MX2014010589A patent/MX345830B/es active IP Right Grant
- 2013-03-05 ES ES13710250.5T patent/ES2676224T3/es active Active
- 2013-03-05 EP EP13710250.5A patent/EP2834243B1/en active Active
- 2013-03-05 AU AU2013230128A patent/AU2013230128B2/en active Active
- 2013-03-05 JP JP2014561024A patent/JP6418950B2/ja active Active
- 2013-03-05 DK DK13710250.5T patent/DK2834243T3/en active
- 2013-03-05 NZ NZ630721A patent/NZ630721A/en unknown
- 2013-03-05 PT PT137102505T patent/PT2834243T/pt unknown
- 2013-03-05 PL PL13710250T patent/PL2834243T3/pl unknown
- 2013-03-05 WO PCT/US2013/029056 patent/WO2013134228A1/en not_active Ceased
- 2013-03-05 CN CN201380012483.0A patent/CN104302649B/zh active Active
- 2013-03-05 IN IN7384DEN2014 patent/IN2014DN07384A/en unknown
- 2013-03-05 KR KR1020147028071A patent/KR101965025B1/ko active Active
- 2013-03-05 TR TR2018/08280T patent/TR201808280T4/tr unknown
- 2013-03-05 CA CA2866143A patent/CA2866143C/en active Active
- 2013-03-08 TW TW102108283A patent/TW201341386A/zh unknown
- 2013-03-11 AR ARP130100765A patent/AR090292A1/es unknown
- 2013-03-11 UY UY0001034668A patent/UY34668A/es not_active Application Discontinuation
-
2014
- 2014-08-21 ZA ZA2014/06149A patent/ZA201406149B/en unknown
- 2014-09-07 IL IL234486A patent/IL234486A/en active IP Right Grant
- 2014-09-11 US US14/483,898 patent/US9403832B2/en active Active
-
2016
- 2016-07-12 US US15/207,677 patent/US20170129896A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1236780A (zh) * | 1998-03-11 | 1999-12-01 | 弗·哈夫曼-拉罗切有限公司 | 吡唑并嘧啶和吡唑并三嗪 |
| WO2011087999A1 (en) * | 2010-01-14 | 2011-07-21 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidines as mark inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104302649B (zh) | 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法 | |
| CN104470523B (zh) | 基于咪唑并[1,2‑b]哒嗪的化合物、包含它们的组合物及其使用方法 | |
| CN105517552A (zh) | 基于咪唑并[1,2-b]哒嗪的化合物、包含它们的组合物及其使用方法 | |
| US9862724B2 (en) | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | |
| CN105934248A (zh) | 取代的吡咯并吡啶和吡咯并吡嗪用于治疗癌症或炎性疾病 | |
| HK1201257B (en) | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | |
| HK1231462B (zh) | 吡啶酮/吡嗪酮、其制备方法及使用方法 | |
| HK1217658B (zh) | 基於吡唑并[1，5-a]嘧啶的化合物、包含其的组合物和其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1201257 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1201257 Country of ref document: HK |